deltatrials
Completed PHASE2 NCT00210379

Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

A Phase II Study of CHOP + Rituximab, With Intrathecal Methotrexate Followed by Radiotherapy in Patients With Primary Testicular Non-Hodgkin's Lymphoma

Sponsor: International Extranodal Lymphoma Study Group (IELSG)

Conditions Lymphoma, B Cell
Interventions CHOP intrathecal methotrexate radiotherapy rituximab
Updated 6 times since 2017 Last updated: Jul 21, 2009 Started: Nov 30, 2000 Primary completion: Nov 30, 2004 Completion: Mar 31, 2007

A PHASE2 clinical study on Lymphoma, B Cell, this trial is completed. The trial is conducted by International Extranodal Lymphoma Study Group (IELSG) and has accumulated 6 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Nov 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • International Extranodal Lymphoma Study Group (IELSG)
Data source: International Extranodal Lymphoma Study Group (IELSG)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bellinzona, Switzerland